vs
富兰克林柯维（FC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是富兰克林柯维的2.0倍（$127.1M vs $64.0M），再鼎医药同比增速更快（17.1% vs -7.3%），富兰克林柯维自由现金流更多（$-1.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.2%）
富兰克林柯维总部位于美国犹他州盐湖城，是一家专业培训指导企业，面向各类组织与个人提供领导力提升、个人效能成长与业务执行领域的培训及评估服务。公司由富兰克林奎斯特与柯维领导力中心于1997年合并成立，最为人熟知的产品包括富兰克林柯维规划系统等。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
FC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的2.0倍
$64.0M
营收增速更快
ZLAB
高出24.4%
-7.3%
自由现金流更多
FC
多$25.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.0M | $127.1M |
| 净利润 | $-3.3M | — |
| 毛利率 | 75.5% | 51.0% |
| 营业利润率 | -5.7% | -54.6% |
| 净利率 | -5.1% | — |
| 营收同比 | -7.3% | 17.1% |
| 净利润同比 | -378.5% | — |
| 每股收益（稀释后） | $-0.27 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCZLAB
| Q4 25 | $64.0M | $127.1M | ||
| Q3 25 | $71.2M | $115.4M | ||
| Q2 25 | $67.1M | $109.1M | ||
| Q1 25 | $59.6M | $105.7M | ||
| Q4 24 | $69.1M | $108.5M | ||
| Q3 24 | $84.1M | $101.8M | ||
| Q2 24 | $73.4M | $100.1M | ||
| Q1 24 | $61.3M | $87.1M |
净利润FCZLAB
| Q4 25 | $-3.3M | — | ||
| Q3 25 | $4.4M | $-36.0M | ||
| Q2 25 | $-1.4M | $-40.7M | ||
| Q1 25 | $-1.1M | $-48.4M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $12.0M | $-41.7M | ||
| Q2 24 | $5.7M | $-80.3M | ||
| Q1 24 | $874.0K | $-53.5M |
毛利率FCZLAB
| Q4 25 | 75.5% | 51.0% | ||
| Q3 25 | 75.5% | 59.5% | ||
| Q2 25 | 76.5% | 60.6% | ||
| Q1 25 | 76.7% | 63.6% | ||
| Q4 24 | 76.3% | 61.5% | ||
| Q3 24 | 78.1% | 64.1% | ||
| Q2 24 | 76.6% | 64.9% | ||
| Q1 24 | 76.4% | 61.4% |
营业利润率FCZLAB
| Q4 25 | -5.7% | -54.6% | ||
| Q3 25 | 11.1% | -42.3% | ||
| Q2 25 | -3.3% | -50.3% | ||
| Q1 25 | -2.4% | -53.3% | ||
| Q4 24 | 2.1% | -62.6% | ||
| Q3 24 | 21.3% | -66.6% | ||
| Q2 24 | 11.4% | -76.0% | ||
| Q1 24 | 2.4% | -80.7% |
净利率FCZLAB
| Q4 25 | -5.1% | — | ||
| Q3 25 | 6.1% | -31.2% | ||
| Q2 25 | -2.1% | -37.3% | ||
| Q1 25 | -1.8% | -45.8% | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 14.2% | -40.9% | ||
| Q2 24 | 7.8% | -80.2% | ||
| Q1 24 | 1.4% | -61.4% |
每股收益（稀释后）FCZLAB
| Q4 25 | $-0.27 | $-0.05 | ||
| Q3 25 | $0.34 | $-0.03 | ||
| Q2 25 | $-0.11 | $-0.04 | ||
| Q1 25 | $-0.08 | $-0.04 | ||
| Q4 24 | $0.09 | $-0.09 | ||
| Q3 24 | $0.89 | $-0.04 | ||
| Q2 24 | $0.43 | $-0.08 | ||
| Q1 24 | $0.06 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.5M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $54.0M | $715.5M |
| 总资产 | $221.3M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FCZLAB
| Q4 25 | $17.5M | $689.6M | ||
| Q3 25 | $31.7M | $717.2M | ||
| Q2 25 | $33.7M | $732.2M | ||
| Q1 25 | $40.4M | $757.3M | ||
| Q4 24 | $53.3M | $779.7M | ||
| Q3 24 | $48.7M | $616.1M | ||
| Q2 24 | $36.6M | $630.0M | ||
| Q1 24 | $40.9M | $650.8M |
股东权益FCZLAB
| Q4 25 | $54.0M | $715.5M | ||
| Q3 25 | $66.9M | $759.9M | ||
| Q2 25 | $65.6M | $791.7M | ||
| Q1 25 | $72.5M | $810.8M | ||
| Q4 24 | $80.6M | $840.9M | ||
| Q3 24 | $83.1M | $667.7M | ||
| Q2 24 | $72.2M | $704.2M | ||
| Q1 24 | $70.8M | $762.2M |
总资产FCZLAB
| Q4 25 | $221.3M | $1.2B | ||
| Q3 25 | $242.9M | $1.2B | ||
| Q2 25 | $218.3M | $1.2B | ||
| Q1 25 | $221.3M | $1.2B | ||
| Q4 24 | $239.9M | $1.2B | ||
| Q3 24 | $261.5M | $985.3M | ||
| Q2 24 | $221.0M | $987.4M | ||
| Q1 24 | $221.9M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.0K | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | -2.5% | -21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $5.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流FCZLAB
| Q4 25 | $98.0K | $-26.0M | ||
| Q3 25 | $9.9M | $-32.0M | ||
| Q2 25 | $6.3M | $-31.0M | ||
| Q1 25 | $-1.4M | $-61.7M | ||
| Q4 24 | $14.1M | $-55.8M | ||
| Q3 24 | $21.9M | $-26.8M | ||
| Q2 24 | $8.2M | $-42.2M | ||
| Q1 24 | $12.8M | $-90.1M |
自由现金流FCZLAB
| Q4 25 | $-1.6M | $-26.7M | ||
| Q3 25 | $5.7M | $-35.0M | ||
| Q2 25 | $4.5M | $-33.9M | ||
| Q1 25 | $-2.6M | $-63.2M | ||
| Q4 24 | $13.1M | $-58.4M | ||
| Q3 24 | $20.8M | $-28.2M | ||
| Q2 24 | $7.3M | $-42.9M | ||
| Q1 24 | $12.1M | $-91.1M |
自由现金流率FCZLAB
| Q4 25 | -2.5% | -21.0% | ||
| Q3 25 | 8.0% | -30.4% | ||
| Q2 25 | 6.7% | -31.1% | ||
| Q1 25 | -4.4% | -59.9% | ||
| Q4 24 | 19.0% | -53.8% | ||
| Q3 24 | 24.7% | -27.7% | ||
| Q2 24 | 9.9% | -42.9% | ||
| Q1 24 | 19.8% | -104.5% |
资本支出强度FCZLAB
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 5.9% | 2.6% | ||
| Q2 25 | 2.7% | 2.6% | ||
| Q1 25 | 2.1% | 1.5% | ||
| Q4 24 | 1.4% | 2.4% | ||
| Q3 24 | 1.3% | 1.3% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 1.0% | 1.1% |
现金转化率FCZLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.27× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 11.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 14.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
